Generation and production of engineered antibodies View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-01

AUTHORS

Sergey M. Kipriyanov, Fabrice Le Gall

ABSTRACT

Various forms of recombinant monoclonal antibodies are being used increasingly, mainly for therapeutic purposes. This review specifically focuses on what is now called antibody engineering, and discusses the generation of chimeric, humanized, and fully human recombinant antibodies, immunoglobulin fragments, and artificial antigen-binding molecules. Since the production of recombinant antibodies is a limiting factor in their availability, and a shortage is expected in the future, different expression systems for recombinant antibodies and transgenic organisms as bioreactors are also discussed, along with their advantages and drawbacks. More... »

PAGES

39-60

References to SciGraph publications

  • 1989-10. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli in NATURE
  • 1996-02-01. High Level Secretion of a Humanized Bispecific Diabody from Escherichia coli in BIO/TECHNOLOGY
  • 1993-01-01. The Effect of Folding Catalysts on the In Vivo Folding Process of Different Antibody Fragments Expressed in Escherichia coli in BIO/TECHNOLOGY
  • 1997-06. Functional expression and germline atransmission of a human chromosome fragment in chimaeric mice in NATURE GENETICS
  • 1991-06. Humanized antibodies for therapy in NATURE
  • 1990-12. Phage antibodies: filamentous phage displaying antibody variable domains in NATURE
  • 1996-09. Phage diabody repertoires for selection of large numbers of bispecific antibody fragments in NATURE BIOTECHNOLOGY
  • 1975-08. Continuous cultures of fused cells secreting antibody of predefined specificity in NATURE
  • 1997-02. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice in NATURE GENETICS
  • 2003-01-21. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library in NATURE BIOTECHNOLOGY
  • 1999-02. Genetic engineering of recombinant glycoproteins and glycosylation pathway in mammalian host cells in GLYCOCONJUGATE JOURNAL
  • 1994. Humanization of Monoclonal Antibodies in THE PHARMACOLOGY OF MONOCLONAL ANTIBODIES
  • 1999-05. Production of goats by somatic cell nuclear transfer in NATURE BIOTECHNOLOGY
  • 1998-07. An efficient route to human bispecific IgG in NATURE BIOTECHNOLOGY
  • 1995-03. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks in NATURE
  • 1988-03. Reshaping human antibodies for therapy in NATURE
  • 1999-09. Generation of recombinant antibodies in MOLECULAR BIOTECHNOLOGY
  • 1998-04. Selection for a periplasmic factor improving phage display and functional periplasmic expression in NATURE BIOTECHNOLOGY
  • 1999-07. Human monoclonal antibodies: The emperor's new clothes? in NATURE BIOTECHNOLOGY
  • 1989-11. Production of antibodies in transgenic plants in NATURE
  • 1986-05. Replacing the complementarity-determining regions in a human antibody with those from a mouse in NATURE
  • 2000-09. Antibody arrays for high-throughput screening of antibody–antigen interactions in NATURE BIOTECHNOLOGY
  • 1996-07. High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice in NATURE BIOTECHNOLOGY
  • 1999-03. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments in NATURE BIOTECHNOLOGY
  • 1995-10. Eukaryotic Virus Display: Engineering the Major Surface Glycoprotein of the Autographa californica Nuclear Polyhedrosis Virus (AcNPV) for the Presentation of Foreign Proteins on the Virus Surface in BIO/TECHNOLOGY
  • 1997-06. Yeast surface display for screening combinatorial polypeptide libraries in NATURE BIOTECHNOLOGY
  • 1983-10. Hybrid hybridomas and their use in immunohistochemistry in NATURE
  • 1997-02. Design and production of novel tetravalent bispecific antibodies in NATURE BIOTECHNOLOGY
  • 2002-08-12. Cloned transchromosomic calves producing human immunoglobulin in NATURE BIOTECHNOLOGY
  • 1998-09. Compartment-specific accumulation of recombinant immunoglobulins in plant cells: an essential tool for antibody production and immunomodulation of physiological functions and pathogen activity in PLANT MOLECULAR BIOLOGY
  • 1998-05. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu in BRITISH JOURNAL OF CANCER
  • Journal

    TITLE

    Molecular Biotechnology

    ISSUE

    1

    VOLUME

    26

    Related Patents

  • Immunoconjugates Targeting Cd138 And Uses Thereof
  • Dual Antigen-Induced Bipartite Functional Complementation
  • Anti-Coagulation Factor Viii Antibody And Use Thereof
  • Trispecific Binding Molecules For Treating Hbv Infection And Associated Conditions
  • Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, And Related Methods
  • Antibodies Against Signal-Regulatory Protein Alpha And Methods Of Use
  • Anti-Pd-1 Antibodies And Methods Of Making And Using Thereof
  • Anti-Cgrp Compositions And Use Thereof
  • Monoclonal Antibody Capable Of Binding To Heparin-Binding Epidermal Growth Factor-Like Growth Factor
  • Anti-Sirpa Antibodies And Methods Of Use Thereof
  • Demibodies: Dimerisation-Activated Therapeutic Agents
  • Glycated Cd59 Peptides, Their Preparation, And Uses Thereof
  • Monoclonal Antibody Capable Of Binding To Heparin-Binding Epidermal Growth Factor-Like Growth Factor
  • Dual Antigen-Induced Bipartite Functional Complementation
  • Anti-Cd79 Antibodies And Their Uses
  • Methods And Agents For Improving Targeting Of Cd138 Expressing Tumor Cells
  • Or10h1 Antigen Binding Proteins And Uses Thereof
  • Thrombin-Binding Antibody Molecules And Uses Thereof
  • Red Blood Cell Targeted Factor Viii And Method Of Using The Same
  • Humanized Anti-Prostate Stem Cell Antigen Monoclonal Antibody
  • Means And Methods For Treating Hbv Infection And Associated Conditions
  • Anti-Cd47 Antibodies And Uses Thereof
  • Anti-Igf Antibodies
  • Anti-Peripheral Lymph Node Addressin Antibodies And Uses Thereof
  • Anti-Cgrp Compositions And Use Thereof
  • Dual Antigen-Induced Bipartite Functional Complementation
  • Monoclonal Antibody Capable Of Binding To Heparin-Binding Epidermal Growth Factor-Like Growth Factor
  • High Functional Bispecific Antibody
  • Anti-Chi3l1 Antibodies For The Detection And/Or Treatment Of Nonalcoholic Fattly Liver Disease/Nonalcoholic Steatonhepatitis And Subsequent Complications
  • Monoclonal Antibody Capable Of Binding To Heparin-Binding Epidermal Growth Factor-Like Growth Factor
  • Anti Notch-1 Antibodies
  • Agents Targeting Cd138 And Uses Thereof
  • Anti-Igf Antibodies
  • Factor Xi Antibodies And Methods Of Use
  • Polypeptides That Bind Complement Component C5 Or Serum Albumin And Fusion Proteins Thereof
  • Cd123 Binding Proteins And Related Compositions And Methods
  • Anti-Human Pd-L2 Antibodies
  • Anti-Igf Antibodies
  • Apoe Immunotherapy
  • Anti-Cgrp Compositions And Use Thereof
  • Combination Therapy For Neoplasia Treatment
  • High Functional Bispecific Antibody
  • Anti-Cgrp Compositions And Use Thereof
  • Apoe Immunotherapy
  • Use Of Anti-Cgrp Antibodies And Antibody Fragments To Prevent Or Inhibit Photophobia Or Light A Version In Subjects In Need Thereof, Especially Migraine Sufferers
  • Antibodies Against Signal-Regulatory Protein Α And Methods Of Use
  • Anti-Lag-3 Antibody
  • Humanised Adamts13 Binding Antibodies
  • Anti-Notch3 Antibodies And Antibody-Drug Conjugates
  • Il-17 Receptor A Antigen Binding Proteins
  • Anti-Igf Antibodies
  • Antibodies Targeting Glycoprotein Vi
  • Anti Notch-1 Antibodies
  • Set Of Polypeptides For Identifying And/Or Eliminating Cells, Use Thereof, Nucleic Acid Molecule Encoding One Of The Polypeptides Of The Set, Set Of Nucleic Acids Encoding The Set Of Polypeptides, Pharmaceutical Composition Comprising These Sets
  • Humanized Anti-S100a9 Antibody And Uses Thereof
  • Anti-Coagulation Factor Xi Antibodies
  • Humanized Anti-Pd-L1 Antibodies
  • Anti-Cgrp Compositions And Use Thereof
  • Polypeptides That Bind Complement Component C5 Or Serum Albumin And Fusion Proteins Thereof
  • Production Of Cytotoxic Antibody-Toxin Fusion In Eukaryotic Algae
  • Demibodies: Dimerisation-Activated Therapeutic Agents
  • Monoclonal Antibody Capable Of Binding To Heparin-Binding Epidermal Growth Factor-Like Growth Factor
  • Anti-Notch1 Antibodies
  • Production Of Cytotoxic Antibody-Toxin Fusion In Eukaryotic Algae
  • Immunoglobulin Constant Region Fc Receptor Binding Agents
  • Acetylenedicarboxyl Linkers And Their Uses In Specific Conjugation Of A Cell-Binding Molecule
  • Reversal Binding Agents For Anti-Factor Xi/Xia Antibodies And Uses Thereof
  • Allergen-Specific Antibodies
  • Anti Notch-1 Antibodies
  • Anti-Cgrp Compositions And Use Thereof
  • Cytotoxic Agents For Conjugation To A Cell Binding Molecule
  • Use Of Anti-Cgrp Antibodies And Antibody Fragments To Treat Diarrhea In Subjects With Diseases Or Treatments That Result In Elevated Cgrp Levels
  • Anti-Pd-L1 Antibodies And Methods Of Using The Same For Detection Of Pd-L1
  • Glycoconjugates And Their Use As Potential Vaccines Against Infection By Shigella Flexneri
  • Antibodies To Lilrb2
  • Use Of Anti-Cgrp Antibodies And Antibody Fragments To Prevent Or Inhibit Photophobia Or Light Aversion In Subjects In Need Thereof, Especially Migraine Sufferers
  • Anti-Cgrp Compositions And Use Thereof
  • Anti-Il-2 Antibodies And Compositions And Uses Thereof
  • Demibodies: Dimerization-Activated Therapeutic Agents
  • Anti-Coagulation Factor Xi Antibodies
  • Anti-Cd3 Antibodies And Uses Thereof
  • Dual Antigen-Induced Bipartite Functional Complementation
  • Glycoconjugates And Their Use As Potential Vaccines Against Infection By Shigella Flexneri
  • Fusion Proteins And Antibodies Targeting Human Red Blood Cell Antigens
  • Acetylenedicarboxyl Linkers And Their Uses In Specific Conjugation Of A Cell-Binding Molecule
  • Anti-Respiratory Syncytial Virus Antibodies, And Methods Of Their Generation And Use
  • Use Of Anti-Cgrp Antibodies And Antibody Fragments To Treat Diarrhea In Subjects With Diseases Or Treatments That Result In Elevated Cgrp Levels
  • Anti-Factor Ix Padua Antibodies
  • Intracellular Nanobody Targeting T4ss Effector Inhibits Ehrlichia Infection
  • Factor Xi Antibodies And Methods Of Use
  • Use Of Anti-Cgrp Antibodies And Antibody Fragments To Prevent Or Inhibit Photophobia Or Light Aversion In Subjects In Need Thereof, Especially Migraine Sufferers
  • Anti-Cgrp Compositions And Use Thereof
  • Antibodies Against N-Acetylglucosamine And N-Acetyl-Galactosamine
  • Use Of Anti-Cgrp Antibodies And Antibody Fragments To Treat Diarrhea In Subjects With Diseases Or Treatments That Result In Elevated Cgrp Levels
  • Cxc-Chemokine Antagonists Isolated From Rhipicephalus Sanguineus
  • Monoclonal Antibody Capable Of Binding To Heparin-Binding Epidermal Growth Factor-Like Growth Factor
  • Specific Conjugation Linkers, Specific Immunoconjugates Thereof, Methods Of Making And Uses Such Conjugates Thereof
  • Acetylenedicarboxyl Linkers And Their Uses In Specific Conjugation Of A Cell-Binding Molecule
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1385/mb:26:1:39

    DOI

    http://dx.doi.org/10.1385/mb:26:1:39

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1007510614

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/14734823


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals, Genetically Modified", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibody Formation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Bioreactors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cloning, Molecular", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Genetic Engineering", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunologic Techniques", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Models, Molecular", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Peptide Library", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Plants, Genetically Modified", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Engineering", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Protein Structure, Tertiary", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Affimed Therapeutics AG, Technologiepark, Im Neuenheimer Feld 582, D-69120, Heidelberg, Germany", 
              "id": "http://www.grid.ac/institutes/grid.432627.6", 
              "name": [
                "Affimed Therapeutics AG, Technologiepark, Im Neuenheimer Feld 582, D-69120, Heidelberg, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kipriyanov", 
            "givenName": "Sergey M.", 
            "id": "sg:person.01121674064.11", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121674064.11"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Le Gall", 
            "givenName": "Fabrice", 
            "id": "sg:person.0671736316.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671736316.47"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nbt0996-1149", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035326507", 
              "https://doi.org/10.1038/nbt0996-1149"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/79494", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047104612", 
              "https://doi.org/10.1038/79494"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0798-677", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040490278", 
              "https://doi.org/10.1038/nbt0798-677"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/256495a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001387921", 
              "https://doi.org/10.1038/256495a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/305537a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010169967", 
              "https://doi.org/10.1038/305537a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/321522a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007617918", 
              "https://doi.org/10.1038/321522a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0297-159", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000258742", 
              "https://doi.org/10.1038/nbt0297-159"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0193-77", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020283412", 
              "https://doi.org/10.1038/nbt0193-77"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/7023", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014744903", 
              "https://doi.org/10.1038/7023"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/342076a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040668704", 
              "https://doi.org/10.1038/342076a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/10798", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006540475", 
              "https://doi.org/10.1038/10798"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0697-553", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017819354", 
              "https://doi.org/10.1038/nbt0697-553"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0296-192", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048103628", 
              "https://doi.org/10.1038/nbt0296-192"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/348552a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009781465", 
              "https://doi.org/10.1038/348552a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0498-376", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028625315", 
              "https://doi.org/10.1038/nbt0498-376"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng0697-133", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021409582", 
              "https://doi.org/10.1038/ng0697-133"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/332323a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016704652", 
              "https://doi.org/10.1038/332323a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.1998.233", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018450644", 
              "https://doi.org/10.1038/bjc.1998.233"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1385/mb:12:2:173", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048541577", 
              "https://doi.org/10.1385/mb:12:2:173"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/8632", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010620958", 
              "https://doi.org/10.1038/8632"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt785", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035469035", 
              "https://doi.org/10.1038/nbt785"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt727", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020880249", 
              "https://doi.org/10.1038/nbt727"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-3-642-78432-3_4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032958507", 
              "https://doi.org/10.1007/978-3-642-78432-3_4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/341544a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030400388", 
              "https://doi.org/10.1038/341544a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/351501a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025716632", 
              "https://doi.org/10.1038/351501a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/374168a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043430559", 
              "https://doi.org/10.1038/374168a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1026466408042", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047429542", 
              "https://doi.org/10.1023/a:1026466408042"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1006029617949", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003895089", 
              "https://doi.org/10.1023/a:1006029617949"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0796-845", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033930326", 
              "https://doi.org/10.1038/nbt0796-845"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng0297-146", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049028548", 
              "https://doi.org/10.1038/ng0297-146"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt1095-1079", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008886313", 
              "https://doi.org/10.1038/nbt1095-1079"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2004-01", 
        "datePublishedReg": "2004-01-01", 
        "description": "Various forms of recombinant monoclonal antibodies are being used increasingly, mainly for therapeutic purposes. This review specifically focuses on what is now called antibody engineering, and discusses the generation of chimeric, humanized, and fully human recombinant antibodies, immunoglobulin fragments, and artificial antigen-binding molecules. Since the production of recombinant antibodies is a limiting factor in their availability, and a shortage is expected in the future, different expression systems for recombinant antibodies and transgenic organisms as bioreactors are also discussed, along with their advantages and drawbacks.", 
        "genre": "article", 
        "id": "sg:pub.10.1385/mb:26:1:39", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1106201", 
            "issn": [
              "1073-6085", 
              "1559-0305"
            ], 
            "name": "Molecular Biotechnology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "26"
          }
        ], 
        "keywords": [
          "recombinant antibodies", 
          "different expression systems", 
          "recombinant monoclonal antibodies", 
          "antibody engineering", 
          "transgenic organisms", 
          "expression system", 
          "human recombinant antibodies", 
          "antigen-binding molecules", 
          "therapeutic purposes", 
          "monoclonal antibodies", 
          "bioreactor", 
          "engineering", 
          "antibodies", 
          "drawbacks", 
          "generation", 
          "production", 
          "advantages", 
          "immunoglobulin fragments", 
          "system", 
          "molecules", 
          "future", 
          "availability", 
          "organisms", 
          "fragments", 
          "shortage", 
          "review", 
          "purpose", 
          "form", 
          "factors"
        ], 
        "name": "Generation and production of engineered antibodies", 
        "pagination": "39-60", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1007510614"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1385/mb:26:1:39"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "14734823"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1385/mb:26:1:39", 
          "https://app.dimensions.ai/details/publication/pub.1007510614"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:24", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_389.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1385/mb:26:1:39"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1385/mb:26:1:39'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1385/mb:26:1:39'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1385/mb:26:1:39'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1385/mb:26:1:39'


     

    This table displays all metadata directly associated to this object as RDF triples.

    284 TRIPLES      21 PREDICATES      102 URIs      63 LITERALS      23 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1385/mb:26:1:39 schema:about N0446b52ea7c94193b495e51be96adff2
    2 N0610e0bac48148f78f055c7aa8cf08a6
    3 N070eef83b6d347c3b688de13900ba7dd
    4 N1bbca16927d2456caafe4891cb34d58b
    5 N1bcc070f85754d70bbbcbf84901b049a
    6 N594d145a9f0c46caa488cf143a0de8d8
    7 N71b76ecf9ac240809659acb2a8086ed7
    8 N9b598716f4f243b58517e5ef12587a24
    9 N9c83f499aa024f1c9d2654910dae6477
    10 Na842a8cbd1284c3eb6c4f93f409320ac
    11 Nab27b997f56b4c57a082f8655cb457aa
    12 Nb3291c5df8004a34b61268c5e43bf749
    13 Nc31c1ae22213408b810bc36516126f85
    14 Ne4c2762ffaab48e48a61183053365338
    15 Ne857b0eb894f4fb094c4f0c63b656efd
    16 Ne8c927ddcb11454e923d258d8b1a5868
    17 anzsrc-for:11
    18 anzsrc-for:1107
    19 schema:author Nbedc8bf2dc934db680fb7a600a2910f1
    20 schema:citation sg:pub.10.1007/978-3-642-78432-3_4
    21 sg:pub.10.1023/a:1006029617949
    22 sg:pub.10.1023/a:1026466408042
    23 sg:pub.10.1038/10798
    24 sg:pub.10.1038/256495a0
    25 sg:pub.10.1038/305537a0
    26 sg:pub.10.1038/321522a0
    27 sg:pub.10.1038/332323a0
    28 sg:pub.10.1038/341544a0
    29 sg:pub.10.1038/342076a0
    30 sg:pub.10.1038/348552a0
    31 sg:pub.10.1038/351501a0
    32 sg:pub.10.1038/374168a0
    33 sg:pub.10.1038/7023
    34 sg:pub.10.1038/79494
    35 sg:pub.10.1038/8632
    36 sg:pub.10.1038/bjc.1998.233
    37 sg:pub.10.1038/nbt0193-77
    38 sg:pub.10.1038/nbt0296-192
    39 sg:pub.10.1038/nbt0297-159
    40 sg:pub.10.1038/nbt0498-376
    41 sg:pub.10.1038/nbt0697-553
    42 sg:pub.10.1038/nbt0796-845
    43 sg:pub.10.1038/nbt0798-677
    44 sg:pub.10.1038/nbt0996-1149
    45 sg:pub.10.1038/nbt1095-1079
    46 sg:pub.10.1038/nbt727
    47 sg:pub.10.1038/nbt785
    48 sg:pub.10.1038/ng0297-146
    49 sg:pub.10.1038/ng0697-133
    50 sg:pub.10.1385/mb:12:2:173
    51 schema:datePublished 2004-01
    52 schema:datePublishedReg 2004-01-01
    53 schema:description Various forms of recombinant monoclonal antibodies are being used increasingly, mainly for therapeutic purposes. This review specifically focuses on what is now called antibody engineering, and discusses the generation of chimeric, humanized, and fully human recombinant antibodies, immunoglobulin fragments, and artificial antigen-binding molecules. Since the production of recombinant antibodies is a limiting factor in their availability, and a shortage is expected in the future, different expression systems for recombinant antibodies and transgenic organisms as bioreactors are also discussed, along with their advantages and drawbacks.
    54 schema:genre article
    55 schema:isAccessibleForFree false
    56 schema:isPartOf N0f31f3079030407a9e354e246f9d12fa
    57 N583af1e1ab9340bda86880a43abb8f00
    58 sg:journal.1106201
    59 schema:keywords advantages
    60 antibodies
    61 antibody engineering
    62 antigen-binding molecules
    63 availability
    64 bioreactor
    65 different expression systems
    66 drawbacks
    67 engineering
    68 expression system
    69 factors
    70 form
    71 fragments
    72 future
    73 generation
    74 human recombinant antibodies
    75 immunoglobulin fragments
    76 molecules
    77 monoclonal antibodies
    78 organisms
    79 production
    80 purpose
    81 recombinant antibodies
    82 recombinant monoclonal antibodies
    83 review
    84 shortage
    85 system
    86 therapeutic purposes
    87 transgenic organisms
    88 schema:name Generation and production of engineered antibodies
    89 schema:pagination 39-60
    90 schema:productId Nce2680d216d5425e8e2d9d26f2cc5cfe
    91 Nd1768247fd0c48278a5c372dbfaa0f1d
    92 Nf2520ada313f49bd9c2c3fb450f248ce
    93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007510614
    94 https://doi.org/10.1385/mb:26:1:39
    95 schema:sdDatePublished 2022-12-01T06:24
    96 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    97 schema:sdPublisher N5fee81ead1d247eba317e15152778ad8
    98 schema:url https://doi.org/10.1385/mb:26:1:39
    99 sgo:license sg:explorer/license/
    100 sgo:sdDataset articles
    101 rdf:type schema:ScholarlyArticle
    102 N0446b52ea7c94193b495e51be96adff2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    103 schema:name Animals, Genetically Modified
    104 rdf:type schema:DefinedTerm
    105 N0610e0bac48148f78f055c7aa8cf08a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    106 schema:name Mice
    107 rdf:type schema:DefinedTerm
    108 N070eef83b6d347c3b688de13900ba7dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    109 schema:name Plants, Genetically Modified
    110 rdf:type schema:DefinedTerm
    111 N0f31f3079030407a9e354e246f9d12fa schema:volumeNumber 26
    112 rdf:type schema:PublicationVolume
    113 N1bbca16927d2456caafe4891cb34d58b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    114 schema:name Cloning, Molecular
    115 rdf:type schema:DefinedTerm
    116 N1bcc070f85754d70bbbcbf84901b049a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Peptide Library
    118 rdf:type schema:DefinedTerm
    119 N583af1e1ab9340bda86880a43abb8f00 schema:issueNumber 1
    120 rdf:type schema:PublicationIssue
    121 N594d145a9f0c46caa488cf143a0de8d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    122 schema:name Bioreactors
    123 rdf:type schema:DefinedTerm
    124 N5fee81ead1d247eba317e15152778ad8 schema:name Springer Nature - SN SciGraph project
    125 rdf:type schema:Organization
    126 N71b76ecf9ac240809659acb2a8086ed7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    127 schema:name Humans
    128 rdf:type schema:DefinedTerm
    129 N9b598716f4f243b58517e5ef12587a24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    130 schema:name Animals
    131 rdf:type schema:DefinedTerm
    132 N9c83f499aa024f1c9d2654910dae6477 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    133 schema:name Immunologic Techniques
    134 rdf:type schema:DefinedTerm
    135 Na842a8cbd1284c3eb6c4f93f409320ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    136 schema:name Antibody Formation
    137 rdf:type schema:DefinedTerm
    138 Nab27b997f56b4c57a082f8655cb457aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Antibodies
    140 rdf:type schema:DefinedTerm
    141 Nb3291c5df8004a34b61268c5e43bf749 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Genetic Engineering
    143 rdf:type schema:DefinedTerm
    144 Nbedc8bf2dc934db680fb7a600a2910f1 rdf:first sg:person.01121674064.11
    145 rdf:rest Ne451e6e2204a49ba917bab96edc93bdc
    146 Nc31c1ae22213408b810bc36516126f85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Antibodies, Monoclonal
    148 rdf:type schema:DefinedTerm
    149 Nce2680d216d5425e8e2d9d26f2cc5cfe schema:name dimensions_id
    150 schema:value pub.1007510614
    151 rdf:type schema:PropertyValue
    152 Nd1768247fd0c48278a5c372dbfaa0f1d schema:name pubmed_id
    153 schema:value 14734823
    154 rdf:type schema:PropertyValue
    155 Ne451e6e2204a49ba917bab96edc93bdc rdf:first sg:person.0671736316.47
    156 rdf:rest rdf:nil
    157 Ne4c2762ffaab48e48a61183053365338 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Models, Molecular
    159 rdf:type schema:DefinedTerm
    160 Ne857b0eb894f4fb094c4f0c63b656efd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Protein Engineering
    162 rdf:type schema:DefinedTerm
    163 Ne8c927ddcb11454e923d258d8b1a5868 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    164 schema:name Protein Structure, Tertiary
    165 rdf:type schema:DefinedTerm
    166 Nf2520ada313f49bd9c2c3fb450f248ce schema:name doi
    167 schema:value 10.1385/mb:26:1:39
    168 rdf:type schema:PropertyValue
    169 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    170 schema:name Medical and Health Sciences
    171 rdf:type schema:DefinedTerm
    172 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    173 schema:name Immunology
    174 rdf:type schema:DefinedTerm
    175 sg:journal.1106201 schema:issn 1073-6085
    176 1559-0305
    177 schema:name Molecular Biotechnology
    178 schema:publisher Springer Nature
    179 rdf:type schema:Periodical
    180 sg:person.01121674064.11 schema:affiliation grid-institutes:grid.432627.6
    181 schema:familyName Kipriyanov
    182 schema:givenName Sergey M.
    183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121674064.11
    184 rdf:type schema:Person
    185 sg:person.0671736316.47 schema:familyName Le Gall
    186 schema:givenName Fabrice
    187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671736316.47
    188 rdf:type schema:Person
    189 sg:pub.10.1007/978-3-642-78432-3_4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032958507
    190 https://doi.org/10.1007/978-3-642-78432-3_4
    191 rdf:type schema:CreativeWork
    192 sg:pub.10.1023/a:1006029617949 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003895089
    193 https://doi.org/10.1023/a:1006029617949
    194 rdf:type schema:CreativeWork
    195 sg:pub.10.1023/a:1026466408042 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047429542
    196 https://doi.org/10.1023/a:1026466408042
    197 rdf:type schema:CreativeWork
    198 sg:pub.10.1038/10798 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006540475
    199 https://doi.org/10.1038/10798
    200 rdf:type schema:CreativeWork
    201 sg:pub.10.1038/256495a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001387921
    202 https://doi.org/10.1038/256495a0
    203 rdf:type schema:CreativeWork
    204 sg:pub.10.1038/305537a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010169967
    205 https://doi.org/10.1038/305537a0
    206 rdf:type schema:CreativeWork
    207 sg:pub.10.1038/321522a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007617918
    208 https://doi.org/10.1038/321522a0
    209 rdf:type schema:CreativeWork
    210 sg:pub.10.1038/332323a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016704652
    211 https://doi.org/10.1038/332323a0
    212 rdf:type schema:CreativeWork
    213 sg:pub.10.1038/341544a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030400388
    214 https://doi.org/10.1038/341544a0
    215 rdf:type schema:CreativeWork
    216 sg:pub.10.1038/342076a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040668704
    217 https://doi.org/10.1038/342076a0
    218 rdf:type schema:CreativeWork
    219 sg:pub.10.1038/348552a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009781465
    220 https://doi.org/10.1038/348552a0
    221 rdf:type schema:CreativeWork
    222 sg:pub.10.1038/351501a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025716632
    223 https://doi.org/10.1038/351501a0
    224 rdf:type schema:CreativeWork
    225 sg:pub.10.1038/374168a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043430559
    226 https://doi.org/10.1038/374168a0
    227 rdf:type schema:CreativeWork
    228 sg:pub.10.1038/7023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014744903
    229 https://doi.org/10.1038/7023
    230 rdf:type schema:CreativeWork
    231 sg:pub.10.1038/79494 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047104612
    232 https://doi.org/10.1038/79494
    233 rdf:type schema:CreativeWork
    234 sg:pub.10.1038/8632 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010620958
    235 https://doi.org/10.1038/8632
    236 rdf:type schema:CreativeWork
    237 sg:pub.10.1038/bjc.1998.233 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018450644
    238 https://doi.org/10.1038/bjc.1998.233
    239 rdf:type schema:CreativeWork
    240 sg:pub.10.1038/nbt0193-77 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020283412
    241 https://doi.org/10.1038/nbt0193-77
    242 rdf:type schema:CreativeWork
    243 sg:pub.10.1038/nbt0296-192 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048103628
    244 https://doi.org/10.1038/nbt0296-192
    245 rdf:type schema:CreativeWork
    246 sg:pub.10.1038/nbt0297-159 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000258742
    247 https://doi.org/10.1038/nbt0297-159
    248 rdf:type schema:CreativeWork
    249 sg:pub.10.1038/nbt0498-376 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028625315
    250 https://doi.org/10.1038/nbt0498-376
    251 rdf:type schema:CreativeWork
    252 sg:pub.10.1038/nbt0697-553 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017819354
    253 https://doi.org/10.1038/nbt0697-553
    254 rdf:type schema:CreativeWork
    255 sg:pub.10.1038/nbt0796-845 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033930326
    256 https://doi.org/10.1038/nbt0796-845
    257 rdf:type schema:CreativeWork
    258 sg:pub.10.1038/nbt0798-677 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040490278
    259 https://doi.org/10.1038/nbt0798-677
    260 rdf:type schema:CreativeWork
    261 sg:pub.10.1038/nbt0996-1149 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035326507
    262 https://doi.org/10.1038/nbt0996-1149
    263 rdf:type schema:CreativeWork
    264 sg:pub.10.1038/nbt1095-1079 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008886313
    265 https://doi.org/10.1038/nbt1095-1079
    266 rdf:type schema:CreativeWork
    267 sg:pub.10.1038/nbt727 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020880249
    268 https://doi.org/10.1038/nbt727
    269 rdf:type schema:CreativeWork
    270 sg:pub.10.1038/nbt785 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035469035
    271 https://doi.org/10.1038/nbt785
    272 rdf:type schema:CreativeWork
    273 sg:pub.10.1038/ng0297-146 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049028548
    274 https://doi.org/10.1038/ng0297-146
    275 rdf:type schema:CreativeWork
    276 sg:pub.10.1038/ng0697-133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021409582
    277 https://doi.org/10.1038/ng0697-133
    278 rdf:type schema:CreativeWork
    279 sg:pub.10.1385/mb:12:2:173 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048541577
    280 https://doi.org/10.1385/mb:12:2:173
    281 rdf:type schema:CreativeWork
    282 grid-institutes:grid.432627.6 schema:alternateName Affimed Therapeutics AG, Technologiepark, Im Neuenheimer Feld 582, D-69120, Heidelberg, Germany
    283 schema:name Affimed Therapeutics AG, Technologiepark, Im Neuenheimer Feld 582, D-69120, Heidelberg, Germany
    284 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...